GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Float Percentage Of Total Shares Outstanding

Paratek Pharmaceuticals (FRA:N4CN) Float Percentage Of Total Shares Outstanding : 82.48% (As of Jun. 10, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Paratek Pharmaceuticals's float shares is 47.28 Mil. Paratek Pharmaceuticals's total shares outstanding is 57.32 Mil. Paratek Pharmaceuticals's float percentage of total shares outstanding is 82.48%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Paratek Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Paratek Pharmaceuticals's Institutional Ownership is 22.84%.

Paratek Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Paratek Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=47.28/57.32
=82.48%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paratek Pharmaceuticals (FRA:N4CN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
ANNX TALS LBPH TCRX AAGH IPSC KPTI INMB DBTX EPIX OCSE:NOVO B VRTX REGN ASX:CSL SGEN MRNA XKRX:207940 XBRU:ARGX BNTX HKSE:02269
Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Website
https://www.paratekpharma.com
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines